MCMichele Cimmino

Michele Cimmino

*This is an algorithmically generated author record based on publicly available information.

Michele Cimmino has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Transcatheter edge-to-edge repair for mitral valve regurgitation: insights from a 5-year prospective multicenter registry

    by Salvatore Giordano, Sabato Sorrentino, Salvatore De Rosa, Marco De Carlo, Marianna Adamo, Elisa Pezzola, Francesco De Felice, Mauro Pennacchi, Emmanuel Villa, Diego Maffeo, et al.

  • Open Access

    Bailout cardiac surgery in patients undergoing transcatheter aortic valve replacement: a comprehensive analysis of post-marketing safety reports

    by Salvatore Giordano, Nicola Corcione, Alberto Morello, Michele Cimmino, Michele Albanese, Paolo Ferraro, Giovanni Vecchione, Ignacio Amat-Santos, Arturo Giordano, Giuseppe Biondi-Zoccai

    Background: Bailout cardiac surgery during transcatheter aortic valve replacement (TAVR) is uncommon but remains associated with substantial morbidity and mortality. Although registries have described its incidence and major causes, they often provide limited detail regarding device-related failure mechanisms, attempted transcatheter rescue, and the clinical pathway leading to surgical conversion. We aimed at analyzing post-marketing safety reports from the U.S. Food and Drug Administration (FDA) Manufacturer and User Facility Device Experience (MAUDE) database to characterize the mechanisms, management strategies, and reported outcomes of bailout surgery during or shortly after TAVR. Methods: We retrospectively analyzed FDA MAUDE reports received from July 1, 2016, through June 30, 2026. Eligible reports described unplanned urgent or emergent open cardiac surgery during or immediately after TAVR. Candidate reports were screened, adjudicated, and deduplicated at the clinical-event level. Events were classified by precipitating complication, transcatheter rescue, operative pathway, and reported outcome. Associations were evaluated using permutation tests, Fisher exact tests with Benjamini–Hochberg correction, adjusted regression models, and sensitivity analyses. Results: After screening 43,239 initial reports, we identified 376 bailout-surgery events, with survival status was documented in 254, including 104 deaths and 150 survivors, corresponding to 40.9% reported mortality. Valve embolization, migration, or malposition was the most frequent complication phenotype (32.4%), whereas ventricular perforation or laceration was associated with the highest mortality (74.1%; OR, 4.86; 95% CI, 1.97–11.99). Mortality differed across complication phenotypes ( p p p =0.355). Valve explantation with SAVR was associated with lower reported mortality (18.9%; OR, 0.29; 95% CI, 0.12–0.69), whereas unspecified surgery or access/support alone was associated with higher mortality (56.9%; OR, 3.04; 95% CI, 1.80–5.12). Ancillary analyses identified potential platform-specific differences in complication and management patterns, while bailout timing was not independently associated with mortality after adjustment. Conclusions: In this MAUDE analysis, bailout cardiac surgery after TAVR was most commonly precipitated by valve embolization, migration, or malposition, whereas ventricular perforation or laceration was associated with the highest reported mortality. Outcomes differed across complication and operative pathways but not across transcatheter rescue strategies or bailout timing after adjustment. These findings identify clinically relevant post-marketing safety signals but should not be interpreted as incidence estimates, comparative device risks, or causal treatment effects.

  • Incidence, Correlates, and Outcomes of Echocardiographic Smoke-Like Effect After Transcatheter Edge-to-Edge Repair of Mitral Regurgitation With the MitraClip Device

    by Nicola Corcione, Paolo Ferraro, Filippo Finizio, Michele Cimmino, Michele Albanese, Alberto Morello, Giuseppe Biondi-Zoccai, Paolo Denti, Antonio Rubbio, Francesco Bedogni, et al.

    The authors aim to appraise the incidence, correlates, and outcomes of the smoke-like effect after transcatheter edge-to-edge repair. Original Contribution from Journal of Invasive Cardiology. MitraClip Mitral regurgitation Mitral Valve Transcatheter Edge-to-Edge Repair transcatheter edge-to-edge repair


  • Open Access

    Transcatheter Mitral Valve Repair With the MitraClip Device for Prior Mitral Valve Repair Failure: Insights From the GIOTTO‐FAILS Study

    by Arturo Giordano, Paolo Ferraro, Filippo Finizio, Nicola Corcione, Michele Cimmino, Giuseppe Biondi‐Zoccai, Paolo Denti, Antonio Popolo Rubbio, Anna Sonia Petronio, Antonio L. Bartorelli, et al.

    Background: Minimally invasive mitral valve repair has a favorable risk–benefit profile in patients with significant de novo mitral regurgitation. Its role in patients with prior mitral valve repair is uncertain. We aimed to appraise the outcome of patients undergoing transcatheter edge‐to‐edge repair (TEER) with prior transcatheter or surgical mitral valve repair (SMVR). Methods and Results: We queried the Italian multicenter registry on TEER with MitraClip, distinguishing naïve patients from those with prior TEER or (SMVR). Inhospital and long‐term clinical/echocardiographic outcomes were appraised. The primary outcome was the occurrence of death or rehospitalization for heart failure. A total of 2238 patients were included, with 2169 (96.9%) who were naïve to any mitral intervention, 29 (1.3%) with prior TEER, and 40 (1.8%) with prior SMVR. Several significant differences were found in baseline clinical and imaging features. Respectively, device success was obtained in 2120 (97.7%), 28 (96.6%), and 38 (95.0%, P =0.261) patients; procedural success in 2080 (95.9%), 25 (86.2%), and 38 (95.0%; P =0.047); and inhospital death in 61 (2.8%), 1 (3.5%), and no ( P =0.558) patients. Clinical follow‐up after a mean of 14 months showed similar rates of death, cardiac death, rehospitalization, rehospitalization for heart failure, and their composite (all P >0.05). Propensity score–adjusted analysis confirmed unadjusted analysis, with lower procedural success for the prior TEER group (odds ratio, 0.28 [95% CI, 0.09–0.81]; P =0.019) but similar odds ratios and hazard ratios for all other outcomes in the naïve, TEER, and SMVR groups (all P >0.05). Conclusions: In carefully selected patients, TEER can be performed using the MitraClip device even after prior TEER or SMVR.


  • Transcatheter Mitral Valve Repair With MitraClip: Comparison of NT, NTr, and XTr Devices

    by Nicola Corcione, Paolo Ferraro, Filippo Finizio, Michele Cimmino, Michele Albanese, Giuseppe Biondi-Zoccai, Paolo Denti, Antonio Rubbio, Antonio Bartorelli, Annalisa Mongiardo, et al.

    In this study, the authors compared NT, NTr, and XTr MitraClip devices for transcatheter edge-to-edge repair. Original Contribution from Journal of Invasive Cardiology. Mitral Valve Transcatheter Edge-to-Edge Repair MitraClip Mitral regurgitation


  • Open Access

    Transcatheter aortic valve implantation with the novel‐generation Navitor device: Procedural and early outcomes

    by Nicola Corcione, Andrea Berni, Paolo Ferraro, Alberto Morello, Michele Cimmino, Michele Albanese, Luisa Nestola, Luca Bardi, Martino Pepe, Salvatore Giordano, et al.

    Transcatheter aortic valve implantation (TAVI) has proved beneficial in patients with severe aortic stenosis, especially when second‐generation devices are used. We aimed at reporting our experience with Navitor, a third‐generation device characterized by intrannular, large cell, and cuffed design, as well as high deliverability and minimization of paravalvular leak. Between June and December 2021, a total of 39 patients underwent TAVI with Navitor, representing 20% of all TAVI cases. Mean age was 80.0 ± 6.7 years, and 14 (36.8%) women were included. Severe aortic stenosis was the most common indication to TAVI (37 [97.4%] cases), whereas 2 (5.3%) individuals were at low surgical risk. Device and procedural success was obtained in all patients, with a total hospital stay of 6.6 ± 4.5 days. One (2.9%) patient required permanent pacemaker implantation, but no other hospital events occurred. At 1‐month follow‐up, a cardiac death was adjudicated in an 87‐year‐old man who had been at high surgical risk. Echocardiographic follow‐up showed no case of moderate or severe aortic regurgitation, with mild regurgitation in 18 (47%), and none or trace regurgitation in 20 (53%). The Navitor device, thanks to its unique features, is a very promising technology suitable to further expand indications and risk‐benefit profile of TAVI.


  • Alex Plus Versus Xience Drug-Eluting Stents for Percutaneous Coronary Intervention in Routine Clinical Practice: A Propensity Score-Matched Analysis

    by Nicola Corcione, Paolo Ferraro, Alberto Morello, Michele Cimmino, Michele Albanese, Martino Pepe, Palma Nestola, Salvatore Giordano, Giuseppe Biondi-Zoccai, Arturo Giordano

    The authors aimed at comparing the effectiveness of Alex Plus and Xience drug-eluting stents in real-world practice.


  • The Novel FlexNav Delivery System for Transcatheter Aortic Valve Implantation With the Portico Device: A Case Series

    by Nicola Corcione, Alberto Morello, Paolo Ferraro, Michele Cimmino, Michele Albanese, Arturo Ausiello, Martino Pepe, Giuseppe Biondi-Zoccai, Arturo Giordano

    We hereby present our preliminary experience with FlexNav in a consecutive series of 18 patients undergoing TAVI with Portico valve in early 2020 (3 with axillary access). Brief Communication from Journal of Invasive Cardiology. aortic stenosis delivery system FlexNav Portico valve


  • Assessing the Best Prognostic Score for Transcatheter Aortic Valve Implantation (from the RISPEVA Registry)

    by Martino Pepe, Nicola Corcione, Anna Sonia Petronio, Sergio Berti, Alessandro Iadanza, Alberto Morello, Palma Luisa Nestola, Gianluigi Napoli, Paolo Ferraro, Michele Cimmino, et al.